1
|
Richards E, Flyckt R, Tzakis A, Quintini C, Hashimoto K, Falcone T. Uterus transplantation: from back table to embryo transfer. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.1124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
2
|
Davis A, Flyckt R, Desai N, Austin C, Tzakis A, Falcone T. IVF cycle characteristics in patients approved for uterine transplantation. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.02.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
3
|
Beran B, Arnolds K, Shockley M, Rivas K, Medina M, Escobar PF, Tzakis A, Falcone T, Sprague ML, Zimberg S. Livebirth and utero-placental insufficiency in Papio hamadryas baboons with uterus angiosome perfused by bilateral utero-ovarian microsurgical anastomoses alone. Hum Reprod 2017; 32:1819-1826. [DOI: 10.1093/humrep/dex242] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 06/21/2017] [Indexed: 01/24/2023] Open
|
4
|
Beran B, Shockley M, Arnolds K, Sprague ML, Zimberg S, Tzakis A, Falcone T. Anatomy of the Internal Iliac Vein: Implications for Uterine Transplant. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Arian S, Flyckt R, Falcone T, Eghtesad B, Fung J, Perni U, Tzakis A. Characteristics of women with uterine factor infertility seeking information on uterine transplantation. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2015.12.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
6
|
Fan J, Tryphonopoulos P, Tekin A, Nishida S, Selvaggi G, Amador A, Jebrock J, Weppler D, Levi D, Vianna R, Ruiz P, Tzakis A. Eculizumab Salvage Therapy for Antibody-Mediated Rejection in a Desensitization-Resistant Intestinal Re-Transplant Patient. Am J Transplant 2015; 15:1995-2000. [PMID: 25649227 DOI: 10.1111/ajt.13183] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Revised: 11/26/2014] [Accepted: 12/19/2014] [Indexed: 01/25/2023]
Abstract
The presence of elevated calculated panel reactive antibody (cPRA) and anti-HLA donor specific antibodies (DSA) are high risk factors for acute antibody-mediated rejection (AAMR) in intestinal transplantation that may lead to graft loss. Eculizumab has been used for the treatment of AAMR in kidney transplantation of sensitized patients that do not respond to other treatment. Here, we report a case where eculizumab was used to treat AAMR in a desensitization-resistant intestinal re-transplant patient. A male patient lost his intestinal graft to AAMR 8.14 years after his primary transplant. He received a second intestinal graft that had to be explanted a month later due to refractory AAMR. The patient remained highly sensitized despite multiple treatments. He received a multivisceral graft and presented with severe AAMR on day 3 posttransplantation. The AAMR was successfully treated with eculizumab. The patient presently maintains an elevated cPRA level above 90% but his DSAs have decreased from 18 000 MFI (mean fluorescent intensity) to below the positive cut-off value of 3000 MFI and remains rejection free with a 2-year follow-up since his multivisceral transplant. Eculizumab offers an alternative to treat AAMR in intestinal transplantation in desensitization-resistant patients.
Collapse
Affiliation(s)
- J Fan
- Miami Transplant Institute, University of Miami, Miami, FL
| | | | - A Tekin
- Miami Transplant Institute, University of Miami, Miami, FL
| | - S Nishida
- Miami Transplant Institute, University of Miami, Miami, FL
| | - G Selvaggi
- Miami Transplant Institute, University of Miami, Miami, FL
| | - A Amador
- Miami Transplant Institute, University of Miami, Miami, FL
| | - J Jebrock
- Miami Transplant Institute, University of Miami, Miami, FL
| | | | - D Levi
- Carolinas Medical Center, Charlotte, NC
| | - R Vianna
- Miami Transplant Institute, University of Miami, Miami, FL
| | - P Ruiz
- Miami Transplant Institute, University of Miami, Miami, FL
| | | |
Collapse
|
7
|
Del Priore G, Saso S, Meslin EM, Tzakis A, Brannstrom M, Clarke A, Vianna R, Sawyer R, Smith JR. Uterine transplantation--a real possibility? The Indianapolis consensus. Hum Reprod 2012. [DOI: 10.1093/humrep/des406] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
8
|
Hibi T, Sageshima J, Molina E, Ciancio G, Nishida S, Chen L, Arosemena L, Mattiazzi A, Guerra G, Kupin W, Tekin A, Selvaggi G, Levi D, Ruiz P, Livingstone AS, Roth D, Martin P, Tzakis A, Burke GW. Predisposing factors of diminished survival in simultaneous liver/kidney transplantation. Am J Transplant 2012; 12:2966-73. [PMID: 22681708 DOI: 10.1111/j.1600-6143.2012.04121.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Since the adoption of the Model for End-Stage Liver Disease, simultaneous liver/kidney transplants (SLKT) have substantially increased. Recently, unfavorable outcomes have been reported yet contributing factors remain unclear. We retrospectively reviewed 74 consecutive adult SLKT performed at our center from 2000 to 2010 and compared with kidney transplant alone (KTA, N = 544). In SLKT, patient and death-censored kidney graft survival rates were 64 ± 6% and 81 ± 5% at 5 years, respectively (median follow-up, 47 months). Multivariable analyses revealed three independent risk factors affecting patient survival: hepatitis C virus positive (HCV+, hazard ratio [HR] 2.9, 95% confidence interval [CI] 1.1-7.9), panel reactive antibody (PRA) > 20% (HR 2.8, 95% CI 1.1-7.2) and female donor gender (HR 2.9, 95% CI 1.1-7.9). For death-censored kidney graft survival, delayed graft function was the strongest negative predictor (HR 8.3, 95% CI 2.5-27.9), followed by HCV+ and PRA > 20%. The adjusted risk of death-censored kidney graft loss in HCV+ SLKT patients was 5.8 (95% CI 1.6-21.6) compared with HCV+ KTA (p = 0.008). Recurrent HCV within 1 year after SLKT correlated with early kidney graft failure (p = 0.004). Careful donor/recipient selection and innovative approaches for HCV+ SLKT patients are critical to further improve long-term outcomes.
Collapse
Affiliation(s)
- T Hibi
- Miami Transplant Institute, University of Miami and Jackson Memorial Hospital, Miami, FL, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Johannesson L, Enskog A, Mölne J, Diaz-Garcia C, Hanafy A, Dahm-Kähler P, Tekin A, Tryphonopoulos P, Morales P, Rivas K, Ruiz P, Tzakis A, Olausson M, Brännström M. Preclinical report on allogeneic uterus transplantation in non-human primates. Hum Reprod 2012; 28:189-98. [PMID: 23108346 DOI: 10.1093/humrep/des381] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
STUDY QUESTION Is it possible to perform allogeneic uterus transplantation (UTx) with a donation from a live donor in a non-human primate species and what immunosuppression is needed to prevent rejection? SUMMARY ANSWER Allogeneic UTx in the baboon is a donor- and recipient-safe surgical procedure; immunosuppression with induction therapy and a triple protocol should be used. WHAT IS KNOWN ALREADY UTx may become a treatment for absolute uterine factor infertility. Autologous UTx models have been developed in non-human primates with reports on long-term survival of the uterine grafts. STUDY DESIGN, SIZEAND DURATION: This experimental study included 18 female baboons as uterus donors and 18 female baboons as uterus recipients. The follow-up time was 5-8 weeks. PARTICIPANTS/MATERIALS, SETTING AND METHODS Uterus retrieval was performed with extended hysterectomy including bilateral uterine and internal iliac arteries and ovarian veins. After UTx, with vascular anastomoses unilateral to the internal iliac artery and the external iliac vein, the uterus recipients received one of the following: no immunosuppression (n = 4); monotherapy (oral slow release tacrolimus) (n = 4) or induction therapy (antithymocyte globulin) followed by triple therapy (tacrolimus, mycophenolate, corticosteroids; n = 10). Surgical parameters, survival, immunosuppression and rejection patterns were evaluated. MAIN RESULTS AND THE ROLE OF CHANCE The durations of uterus retrieval and recipient surgery were around 3 and 3.5 h, respectively. The total ischemic time was around 3 h. All the recipients and the donors survived the surgery. All the recipients presented rejection to some extent within the first weeks following UTx. In one recipient, the uterus was of normal appearance at the end of the study period. In spite of occasional high (>60 ng/ml) blood levels of tacrolimus, there was no evidence of nephrotoxicity. LIMITATIONS AND REASONS FOR CAUTION This initial non-human primate allogeneic UTx study indicates that further research is needed to optimize immunosuppression protocols in order to avoid uterine rejection. WIDER IMPLICATIONS OF THE FINDINGS The findings suggest that allogeneic UTx in primate species is feasible but continued work on this issue is needed. STUDY FUNDING/COMPETING INTEREST(S) The study was funded by the Swedish Research Council, ALF University of Gothenburg, Hjalmar Svensson Foundation and by Jane and Dan Olsson Research Foundation. The authors do not have any competing interest.
Collapse
Affiliation(s)
- L Johannesson
- Department of Obstetrics and Gynecology, Sahlgrenska Academy, Sahlgrenska University Hospital, University of Gothenburg, 413 45 Göteborg, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Kato T, Lobritto SJ, Tzakis A, Raveh Y, Sandoval PR, Martinez M, Granowetter L, Armas A, Brown RS, Emond J. Multivisceral ex vivo surgery for tumors involving celiac and superior mesenteric arteries. Am J Transplant 2012; 12:1323-8. [PMID: 22300017 DOI: 10.1111/j.1600-6143.2011.03945.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Abdominal tumors involving both roots of the celiac and superior mesenteric artery are deemed unresectable by conventional surgical methods. We performed three cases of multivisceral ex vivo surgery involving temporary removal of the entire abdominal viscera followed by vascular reconstruction, ex vivo tumor resection and autotransplantation of excised organs. We achieved a complete tumor resection with negative margins in all cases. All patients have survived with no tumor recurrence to date at 17-, 27- and 38-month follow-up. Postoperative complications included diarrhea, sphincter of Oddi dysfunction and arterial stenosis; all responded to directed treatments. Multivisceral ex vivo surgery applying techniques of deceased donor multivisceral transplantation is feasible in achieving local control of otherwise unresectable abdominal tumors. This surgery is best suitable for locally invasive tumors unresectable because of location and vascular involvement.
Collapse
Affiliation(s)
- T Kato
- Department of Surgery, Columbia University Medical Center, New York, NY, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Nesher E, Island E, Tryphonopoulos P, Moon J, Nishida S, Selvaggi G, Tekin A, Levi DM, Tzakis A. Split liver transplantation. Transplant Proc 2011; 43:1736-41. [PMID: 21693268 DOI: 10.1016/j.transproceed.2010.11.031] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2010] [Revised: 10/29/2010] [Accepted: 11/03/2010] [Indexed: 11/24/2022]
Abstract
We analyzed the results of 55 patients who underwent split liver transplantation at our center between September 1996 and December 2008, 30 adults (54.5%) and 25 children (45.5%). Median follow-up was 12 years. Overall patient survival was 71%, adult 70% and pediatric 72%. Mean patient survival was 61.58 months, and mean graft survival was 44.35 months. Pediatric survival and pediatric graft survival after 1 and 5 years were 84% and 72% and 72% and 52.4%, respectively. Adult survival and adult graft survival after 1 and 5 years were 75% and 66.2% and 60.7% and 51.5%, respectively. Twelve patients required retransplantation, 6 for primary nonfunction, 3 for chronic rejection, and 3 for vascular complications. Blood groups of the recipient patients were: 34 O, 14 A, 7 B, and 0 AB. The use of split liver for adult and pediatric populations allows us to expand the cadaveric donor pool and has the potential to significantly reduce waiting list mortality, especially for certain blood groups.
Collapse
Affiliation(s)
- E Nesher
- Division of Transplantation, Department of Surgery, University of Miami School of Medicine, Miami, Florida 33136, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Diaz-Garcia C, Johannesson L, Enskog A, Tzakis A, Olausson M, Brannstrom M. Uterine transplantation research: laboratory protocols for clinical application. Mol Hum Reprod 2011; 18:68-78. [DOI: 10.1093/molehr/gar055] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
13
|
Maganty K, Ghanta R, Bejarano P, Weppler D, Tekin A, Moon J, Nishida S, Tzakis A, Martin P. Liver Transplantation for Hepatopulmonary Syndrome Due to Noncirrhotic Portal Hypertension. Transplant Proc 2011; 43:2814-6. [DOI: 10.1016/j.transproceed.2011.07.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Accepted: 07/18/2011] [Indexed: 12/24/2022]
|
14
|
Johannesson L, Enskog A, Dahm-Kahler P, Diaz-Garcia C, Tzakis A, Olausson M, Brannstrom M, Zavos A, Polyzos NP, Dragamestianos C, Blockeel C, Papanikolaou EG, Stoop D, De Vos M, Tournaye H, Devroey P, Messinis IE, Leonardi M, Benaglia L, Somigliana E, De Benedictis S, Scarduelli C, Ragni G, Sugiyama R, Nakagawa K, Nishi Y, Jyuen H, Kuribayashi Y, Sugiyama R, Inoue M, Motoyama K, Akira S, Diaz-Garcia C, Akhi SN, Brannstrom M. SELECTED ORAL COMMUNICATION SESSION, SESSION 44: SURGERY, Tuesday 5 July 2011 15:15 - 16:30. Hum Reprod 2011. [DOI: 10.1093/humrep/26.s1.44] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Ohira M, Nishida S, Tryphonopoulos P, Tekin A, Selvaggi G, Moon J, Levi D, Feun LG, Ruiz P, Ricordi C, Ishiyama K, Ohdan H, Tzakis A. A novel concept of adoptive immunotherapy using interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
TSAI H, Tzakis A, Gonzalez-Pinto I, CHANG J, Tryphonopoulos P, Nishida S, Island E, Selvaggi G, Tekin A, Moon J, Levi D, Woodle ES, Ruiz P. ANTI-DONOR SPECIFIC ANTIBODIES ASSOCIATED WITH ACUTE REJECTION IN THE EARLY POST-TRANSPLANT PERIOD OF SMALL BOWEL AND MULTIVISCERAL ALLOGRAFT RECIPIENTS. Transplantation 2010. [DOI: 10.1097/00007890-201007272-00667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Sotolongo B, Asaoka T, Island E, Carreno M, Delacruz V, Cova D, Russo C, Tryphonopoulos P, Moon J, Weppler D, Tzakis A, Ruiz P. Gene Expression Profiling of MicroRNAs in Small-Bowel Transplantation Paraffin-Embedded Mucosal Biopsy Tissue. Transplant Proc 2010; 42:62-5. [DOI: 10.1016/j.transproceed.2009.12.018] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
18
|
Yandza T, Schneider S, Nishida S, Goubaux B, Badan L, Vanbiervliet G, Saint-Paul M, Bernard G, Laffont C, Gari-Toussaint M, Girard-Pipau F, Miton V, Rahili A, Zeanandin G, Benchimol D, Tzakis A, Gugenheim J, Hébuterne X. Outcome of Exfoliative Rejection After Isolated Intestinal Transplantation in an Adult: Case Report. Transplant Proc 2010; 42:100-2. [DOI: 10.1016/j.transproceed.2009.12.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Selvaggi G, Tzakis A. Surgical considerations in liver transplantation: small for size syndrome. Panminerva Med 2009; 51:227-233. [PMID: 20195233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The chronic shortage of cadaveric grafts for patients on the liver transplant list has resulted in wide implementation of living donor liver transplant (LDLT) and split cadaveric liver transplantation (SLT). Small for size syndrome (SFSS) is a significant complication that can occur during LDLT or SLT. It is generally defined as the presence of prolonged cholestasis, coagulopathy and ascites within the first week from transplant. Multiple factors contribute to the pathogenesis of SFSS, such as overall graft size, portal hyperperfusion, impaired venous outflow, as well as donor and recipient factors. Strategies utilized to minimize or resolve SFSS include the use of right lobe grafts, modulation of portal flow by splenic artery ligation, splenectomy or porto-systemic bypass, and optimization of venous outflow. Additional surgical techniques to avoid SFSS include the use of auxiliary orthotopic liver grafts and dual liver graft transplantation. Careful consideration of risk to the LDLT donor has to be taken whenever right lobe graft is utilized, especially if the middle hepatic vein (MVH) is going to be included in the graft.
Collapse
Affiliation(s)
- G Selvaggi
- University of Miami Miller School of Medicine, Miami Transplant Institute, Miami, FL, USA.
| | | |
Collapse
|
20
|
Garrison A, Morris M, Doblecki Lewis S, Smith L, Cleary T, Procop G, Vincek V, Rosa-Cunha I, Alfonso B, Burke G, Tzakis A, Hartstein A. Mycobacterium abscessusinfection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11:541-8. [DOI: 10.1111/j.1399-3062.2009.00434.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
21
|
Feun LG, Levi D, Moon J, Nishida S, Island E, Selvaggi G, Martin P, Savaraj N, Mendes F, Tzakis A. Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15579] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15579 Background: Sorafenib has been approved for the treatment of advanced HCC. However, there is no data on its use for HCC patients (pts) after liver transplantation (OLT). Pts at high risk for tumor recurrence (native liver showing vascular invasion, multiple tumors >3 in number, size >6 cm, or lymph node involved) after OLT or who develop recurrence after OLT have worse prognosis. These pts may potentially benefit from sorafenib. Methods: We reviewed our experience with HCC pts after OLT treated with sorafenib. 15 pts had a starting dose of 400 mg po bid and 3 had a starting dose of 200 po bid. Sorafenib was started 3 months (mo) after OLT as adjuvant therapy (7 pts) or at the time of tumor recurrence after OLT (11 pts). CT or MRI scans of the chest/abdomen and physical exams were performed every 2–3 mo. Lab tests including serum AFP were performed monthly. Results: Median age was 60 (range 53–75). Median performance status was 90%(range 80–100). In terms of toxicity, 4 of the 15(27%) pts on the initial dose of 400 mg bid stopped sorafenib due to unacceptable toxicity and 5 (33%) had dose reduction due to toxicity. Grade 3/4 toxicity included skin rash, fatigue and anorexia, hyperbilirubinemia, chest/abdominal pain. Only 40% could continue at the full recommended starting dose of sorafenib.For the 11 pts with recurrent disease after OLT treated with sorafenib, the sites of evaluable disease include liver (5 pts), lung (3), others (3). One pt (9%) had a partial response in lung metastases for 10 mo. and the median time to tumor progression (TTP) was 4 mo. (range 2–10 mo). For pts on adjuvant sorafenib after OLT, no pt has relapsed so far with a median followup of 6+ mo. (range 2+ to 15+ mo). Conclusions: The response rate and TTP for pts treated with sorafenib for recurrent HCC after OLT is similar to HCC pts without OLT (Llovet, NEJM 2008). Since the majority of HCC pts after OLT treated with sorafenib required either dose reduction or stoppage due to toxicity which is higher than previously reported, a lower starting dose with dose escalation may be preferred. Contributing factors for toxicity may include the anti-rejection drugs (tacrolimus, mycophenolate, steroids) used for OLT which might affect pharmacokinetics(PK) of sorafenib. Further PK studies with sorafenib in HCC pts after OLT for future clinical trials are indicated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - D. Levi
- University of Miami, Miami, FL
| | - J. Moon
- University of Miami, Miami, FL
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Takahashi H, Ruiz P, Ricordi C, Miki A, Mita A, Barker S, Tzakis A, Ichii H. In situ quantitative immunoprofiling of regulatory T cells using laser scanning cytometry. Transplant Proc 2009; 41:238-9. [PMID: 19249524 DOI: 10.1016/j.transproceed.2008.10.060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2008] [Accepted: 10/06/2008] [Indexed: 01/22/2023]
Abstract
Laser scanning cytometry (iCys; CompuCyte, Cambridge, Mass) has recently been developed to use fluorescence-based quantitative measurements on tissue sections or other cellular preparations at a single-cell level. The purpose of this study was to develop objective, quantitative immunoprofiling of regulatory T cells (T regs) on formalin-fixed/paraffin-embedded (FFPE) biopsy samples from transplanted allografts using iCys. We sought to evaluate the usefulness of iCys to analyzes the population of CD4 (+) Foxp3 (+) T regs among CD4 (+) T-cell and the entire T-cell (the total of CD4 [+] and CD8 [+] populations in human intestinal allograft biopsy samples. Primary antibodies (Foxp3 and CD4) which had been labeled using Alexa Fluoro 488 (Foxp3 Alexa488) and 647 (CD4 Alexa647) with polymer horseradish peroxidase and catalyzed signal amplification were incubated on 1 section. On the other section, CD8 and CD4 were labeled using Alexa488 and Alexa647 using the same protocol. Data acquisition was performed using iCys. The signal intensities of Alexa488 and Alexa647 were sufficient to analyze by iCys. Distribution of the integrals of Alexa488 and Alexa647 to visualize each cell population enabled calculation of the population of T reg among CD4 (+) T cells, CD4 (+) T cells among total T cells, and T reg among entire T cells. iCys and signal amplified immunofluorescent staining allowed objective quantitative immunoprofiling of in situ T reg populations, with precise quantitative analysis at a single-cell level on FFPE sections. This objective method may be applied on biopsy samples from various transplanted organs.
Collapse
Affiliation(s)
- H Takahashi
- Department of Surgery, University of Miami School of Medicine, Miami, Florida 33136, USA
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Lichtenberger P, Rosa-Cunha I, Morris M, Nishida S, Akpinar E, Gaitan J, Tzakis A, Doblecki-Lewis S. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. Transpl Infect Dis 2008; 11:137-42. [PMID: 19144097 DOI: 10.1111/j.1399-3062.2008.00358.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Severe strongyloidiasis, including hyperinfection and dissemination, is a recognized complication of solid organ transplantation. However, the development of strongyloidiasis in a liver transplant recipient has not been previously described. We present a case of severe strongyloidiasis occurring in a patient 4 months after liver transplantation and 1 month after receiving treatment for acute rejection. We assess the management challenges in this patient who remained symptomatic despite oral treatment with ivermectin and albendazole and eventual successful treatment with parenteral ivermectin. We review the published experience with alternative methods of ivermectin administration. We also investigate the possible source of infection, as the patient was not from an endemic area.
Collapse
Affiliation(s)
- P Lichtenberger
- Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, Florida 33136, USA
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Kato T, Selvaggi G, Burke G, Ciancio G, Zilleruelo G, Hattori M, Gosalbez R, Tzakis A. Partial bladder transplantation with en bloc kidney transplant--the first case report of a 'bladder patch technique' in a human. Am J Transplant 2008; 8:1060-3. [PMID: 18312611 DOI: 10.1111/j.1600-6143.2008.02180.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Transplantation of the urinary bladder has not been reported in humans. We transplanted a portion of the donor bladder with an en bloc kidney graft in a 12-month-old girl. The child had a congenital hypoplastic single kidney with an ectopic ureteral opening into the vagina. Her native bladder was extremely small. Bilateral kidneys were transplanted en bloc with their ureters connected to a patch of the donor bladder, which encompassed the bilateral ureterovesical junctions (UVJs) (bladder patch technique). Approximately one-third of the donor bladder wall was used. The bladder patch reperfused well via blood supply from the ureters. Posttransplant cystoscopy with retrograde cystogram revealed a viable transplanted bladder with normal emptying of transplanted ureters. No reflux across the donor UVJs was seen in a voiding cystourethrogram. The child is doing well with normal renal function at 18-month follow-up.
Collapse
Affiliation(s)
- T Kato
- Division of Transplant, University of Miami, Miami, FL, USA.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Kleiner G, Barredo J, Shariatmadar S, Khan A, Pahwa R, Rodriguez M, Willumsen S, Podda A, Fernandes C, Alvarez O, Kritzer-Cheren M, Tzakis A, Rubinstein P, Kurtzberg J. 241: Successful Combined Unrelated Umbilical Cord Blood Haploidentical Transplant in Non Malignant Disease. Biol Blood Marrow Transplant 2008. [DOI: 10.1016/j.bbmt.2007.12.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Taffaro M, Pyrsopoulos N, Cedron H, Cacayorin E, Weppler D, Moon J, Nishida S, Levi D, Kato T, Selvaggi G, Tzakis A, Schiff E. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report. Dig Dis Sci 2007; 52:3435-7. [PMID: 17431776 DOI: 10.1007/s10620-006-9721-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2006] [Accepted: 12/03/2006] [Indexed: 12/09/2022]
Affiliation(s)
- M Taffaro
- University of Miami Center for Liver Disease and Division of Liver/GI Transplantation, Miami, Florida, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Kato T, Selvaggi G, Panagiotis T, Hernandez E, McLaughlin G, Moon J, Nishida S, Levi D, Thompson J, Halliday N, Ruiz P, Tzakis A. Pediatric liver transplant with Campath 1H induction--Preliminary report. Transplant Proc 2007; 38:3609-11. [PMID: 17175346 DOI: 10.1016/j.transproceed.2006.10.039] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2006] [Indexed: 11/23/2022]
Abstract
UNLABELLED Since Campath 1H (C1H) has been successfully used in adult liver transplant recipients since 2001 in our program, we started to use it in children. PATIENTS AND METHODS C1H induction was employed in 10 children with autoimmune hepatitis (AIH) (n = 6), primary sclerosing cholangitis (PSC) (n = 1), biliary atresia (n = 1), glycogen storage disease (n = 1), and Wilson's disease. Eight were primary transplants, and two retransplants. Patients ages ranged from 5 to 17 years. C1H was administered at a dose of 0.3 mg/kg on days 0, 4, and 7. Tacrolimus level was maintained at 5 to 10 ng/mL. No patient received maintenance steroids posttransplantation except two who were on steroid therapy at the time transplant. They were prescribed small doses of maintenance steroids. Median follow-up of C1H recipients was 679 days (range 115-1143). RESULTS Postoperative courses were mostly uneventful except for one retransplant recipient who required prolonged hospitalization (40 days) for rehabilitation. Median hospital stay was 12 days (range 7-40 days). All 10 patients in the C1H group are currently alive and well with stable graft function. No opportunistic infection was observed in these patients to date. We compared six patients with AIH who received C1H to the historic control of 10 recipients with AIH who received conventional immunosuppression (tacrolimus + steroid). The patients treated with C1H showed significantly prolonged rejection-free survival. CONCLUSION In our preliminary experience, C1H induction was well tolerated in pediatric liver recipients. Rejections-free survival was prolonged among recipients with AIH despite a low level of maintenance immunosuppression.
Collapse
Affiliation(s)
- T Kato
- Department of Surgery, University of Miami, Liver and GI Transplant, Miami, Florida 33136, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Gandia C, David A, Santiago S, Ruiz P, Tzakis A, Kleiner G. 193: Intestinal tissue engineering. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2006.12.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Kato T, Selvaggi G, Levi D, Hernandez E, Takahashi H, Velasco M, Moon J, Nishida S, Thompson J, Ruiz P, Sfakianakis G, Tzakis A. Routine Use of Auxiliary Partial Orthotopic Liver Transplantation for Children With Fulminant Hepatic Failure: Preliminary Report. Transplant Proc 2006; 38:3607-8. [PMID: 17175345 DOI: 10.1016/j.transproceed.2006.10.038] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2006] [Indexed: 01/22/2023]
Abstract
Auxiliary partial orthotopic liver transplantation (APOLT) has been performed for both metabolic disorders and fulminant liver failure (FHF). When the native liver regenerates, the patients with FHF who undergo APOLT have a chance to withdraw immunosuppression. It may be most beneficial for children. This preliminary report describes our start to routinely offer APOLT as an option to standard OLT for children with FHF in 2005. Six children (ages 8 months to 8 years) received APOLT: 1 in 1996 and the others in 2005 and 2006. The donor ages ranged from 4 to 40 years. We used either a left lateral segment or a left lobe graft. The recipient left lobe, which was removed, showed submassive to massive necrosis at the time of transplantation. All children are alive and well. The first patient who received APOLT in 1996 is currently off immunosuppression with a fully recovered native liver; the grafted liver underwent complete atrophy. The 5 remaining subjects are receiving reduced levels of immunosuppression with close monitoring. Their serial liver biopsy specimens show slight to significant recovery. One developed hepatic artery thrombosis, requiring retransplantation. The native liver was retained at the time of retransplantation (redo APOLT). Other postoperative complications included a bile leak (n = 1), invasive mucomycosis of the arm (preexisting condition; n = 1), biliary stricture (n = 1), and acute cellular rejection (n = 3). Posttransplantation length of stay was 6 to 60 days (median, 15 days). In conclusion, APOLT can be safely performed in children with FHF displaying short-term outcomes comparable to standard transplantations.
Collapse
Affiliation(s)
- T Kato
- Department of Liver and GI Transplant, University of Miami, Liver and Gastrointestinal Transplant, Miami, Florida 33136, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Wada M, Kato T, Hayashi Y, Selvaggi G, Mittal N, Thompson J, Gonzalez M, Nishida S, Madariaga J, Tzakis A. Intestinal transplantation for short bowel syndrome secondary to gastroschisis. J Pediatr Surg 2006; 41:1841-5. [PMID: 17101355 DOI: 10.1016/j.jpedsurg.2006.06.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND/PURPOSE Gastroschisis is the most frequent cause of pediatric intestinal transplantation. This study reviews our experience of intestinal transplantation secondary to gastroschisis to elucidate those factors affecting the outcome of children with short bowel syndrome. METHODS A retrospective review was performed for children who underwent intestinal transplantation for gastroschisis at the University of Miami between June 2003 and August 1994. RESULTS Thirty-two transplants were performed in 28 children with gastroschisis during the study period. Associated intestinal anomalies were present in 22 infants (atresia [n = 14], volvulus [n = 3], and/or ischemia [n = 16]). Spontaneous prenatal closure of gastroschisis, a rare anomaly associated with bowel atresia and ischemia because of a very small abdominal defect, was seen in 9 patients. Most of the patients had a complicated course and required multiple abdominal surgeries before transplant. Fifteen (53.6%) patients are currently alive at a median follow-up of 23.5 months. Short-term survival rate has significantly improved in recent years. CONCLUSIONS Patients with complex gastroschisis and intestinal anomalies have a significant risk for progression to short bowel syndrome. Intestinal transplantation can be a lifesaving option and provides a satisfactory outcome for children with short bowel syndrome secondary to gastroschisis.
Collapse
Affiliation(s)
- Motoshi Wada
- Department of Pediatric Surgery, Tohoku University School of Medicine, Sendai 980-8574, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ueno T, Kato T, Gaynor J, Velasco M, Selvaggi G, McLaughlin G, Hernandez E, Thompson J, Tzakis A. Temporary elevation of serum transaminases after pediatric intestinal transplantation: incidence and clinical correlation in multivisceral transplant vs isolated intestinal transplant. Transplant Proc 2006; 38:1765-7. [PMID: 16908275 DOI: 10.1016/j.transproceed.2006.05.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Data were gathered from the records of 51 children of median age 1.5 years who survived more than 6 months after intestinal transplantation. Abnormal liver function tests (LFTs) were defined as serum aspartate aminotransferase (AST) greater than 100 IU/L or total bilirubin greater than 2.0 g/dL lasting more than 3 days. Temporary elevation was defined when LFTs returned to normal without graft loss or death. LFT elevation at the time of transplantation was not included as a temporary LFT elevation. Median follow-up was 36 months. In multivisceral transplant recipients, all patients (n = 34) showed abnormal LFTs at transplantation that normalized within a median period of 2 days. Temporary LFT elevations were seen in 20 of 34 (59%) in multivisceral transplantation and 5 of 17 (29%) in isolated intestinal transplantation. Median length of elevation was 14 days in multivisceral transplantation and 12 days in isolated intestinal transplantation. Peak AST was 353 +/- 190 IU/dL in multivisceral transplantation and 839 +/- 605 IU/dL in isolated intestinal transplantation (P = .0059). Events associated with temporary LFT elevations in multivisceral transplantation were total parental nutrition (TPN) (n = 8), dehydration (n = 2), viral infection (n = 2), others (n = 3), and nonspecific (n = 5). Events in isolated intestinal transplantation were posttransplant lymphoproliferative disorder (n = 2), TPN (n = 1), and nonspecific (n = 2). Temporary LFT elevations were commonly seen among pediatric intestinal recipients, which correlated with events other than rejection. Approximately half of the temporary LFT elevations were associated with no significant clinical events. They resolved spontaneously. Interestingly, the peak AST value was higher in isolated intestinal transplantation compared to multivisceral transplantation.
Collapse
Affiliation(s)
- T Ueno
- GI/Liver Transplant, Department of Surgery, University of Miami/Jackson Memorial Medical Center, 1801 NW 9th Avenue, Miami, FL 33136, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Ruiz P, Weppler D, Nishida S, Kato T, Selvaggi G, Levi D, Bejarano P, Khaled A, Tryphonopoulos P, Tuteja S, Garcia M, Tzakis A. International grading scheme for acute rejection in small bowel transplantation: implementation and experience at the University of Miami. Transplant Proc 2006; 38:1683-4. [PMID: 16908246 DOI: 10.1016/j.transproceed.2006.05.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
In 2003, an international collection of pathologists and clinicians proposed a unified grading system for acute cellular rejection in endoscopically derived small intestine allograft biopsies. This grading system was implemented at the University of Miami over the past 2 years and the results are presented herein. A total of 1136 small bowel allograft biopsies with sufficient tissue for analysis were obtained from 123 hospitalized, clinic, and referral patients. The overall most common diagnosis assessing all time periods was grade IND (40%), and grade 1 rejection or greater was present in 19% percent of biopsies. A suspected vascular component to the acute rejection as identified by specific mucosal vascular changes was present in 6% of cases. Clinical decision making was very consistent with different grades. Our experience has confirmed that this new grading system is reliable and identifies clinical subsets of patients that can receive different therapy. We recommend that this international grading system be implemented for acute cellular rejection in bowel allografts as a means to standardize pathological assessment of alloimmune-induced graft injury, which will allow comparisons between different centers and clinical trials.
Collapse
Affiliation(s)
- P Ruiz
- Department of Pathology, University of Miami School of Medicine, 1611 NW 12th Avenue, JMH Holtz Center #2101, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Kato T, Selvaggi G, Gaynor J, Madariaga J, McLaughlin G, Thompson J, Nishida S, Moon J, Levi D, Ruiz P, Tzakis A. Expanded use of multivisceral transplantation for small children with concurrent liver and intestinal failure. Transplant Proc 2006; 38:1705-8. [PMID: 16908255 DOI: 10.1016/j.transproceed.2006.05.060] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Fifty-five children with liver and intestinal failure have been transplanted at our center under daclizumab induction therapy since 1998. Of those, 19 received five multiviceral transplantation (MVT), 12 liver-intestine-pancreas transplants, and 2 noncomposite liver and intestine transplants (NCLIT) before 2001 (group 1). During this period, MVT was only used in children with gastric dysmotility. After 2001, we expanded the use of MVT. Therefore, 36 children in this period (group 2) received MVT except for two who received NCLIT. Median age was 1.08 in group 1 and 1.06 in group 2. Median recipient weight was 8.2 kg in group 1 and 7.5 kg in group 2. Six-month, 1-, and 2-year patient survivals were 54%, 37%, and 32% in group 1 and 94%, 91%, and 71% in group 2 (P = .00037). A statistically significant difference was observed in freedom from rejection between the two groups with group 2 being favorable (P = .0019). A statistically significant difference was observed in freedom from rejection between the two groups with group 2 being favorable (P = .0019) Four died of rejection in group 1 (21%); none died of rejection in group 2. There have been two esophago-gastrostomy strictures (one in each group) and a serious reflux of this anastomosis (group 2). Strictures were treated with balloon dilatation, and the reflux was surgically corrected. In 24 recent cases, gastro-gastric anastomosis was used in MVT with no complications to date. No pancreatic rejection was seen. Small children tolerated MVT with improved survival rates and reduced rates of rejection. Use of MVT may be considered as an alternative to liver-intestine-pancreas transplant.
Collapse
Affiliation(s)
- T Kato
- Divisions of Transplant, Pediatric Gastroenterology, Pediatric Critical Care Medicine, and Immunopathology, University of Miami, School of Medicine, 1801 NW 9th Avenue, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Kato T, Kleiner G, David A, Selvaggi G, Nishida S, Madariaga J, Thompson J, Ruiz P, Tzakis A. Inclusion of spleen in pediatric multivisceral transplantation. Transplant Proc 2006; 38:1709-10. [PMID: 16908256 DOI: 10.1016/j.transproceed.2006.05.059] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Inclusion of the donor spleen may be beneficial for small children who receive multivisceral transplantation (MVT) because asplenia is associated with increased risk of bacterial sepsis. Beginning in 2003, the spleen was transplanted together with multivisceral transplantation in 17 children under daclizumab induction (spleen group). The results were compared to 23 children who received multivisceral transplantation without the spleen (control group) with the same immunosuppression regimen. Median age of 17 patients who received a spleen was 0.80 years (range 0.54-1.66). Platelet counts at 30 and 60 days posttransplant were significantly lower in the spleen group (average values: day 30: 399,000 vs 636,000, P = .015; day 60: 413,000 vs 622,000, P = .0056). WBC counts at 30 and 60 days posttransplant were also decreased in the spleen group but the difference was not statistically significant. Median rejection-free survival was 205 days in the spleen group and 101 days in the control group (P = NS). Median length of hospital stay was 39 days in the spleen group and 61 days in the control group. With a median follow-up of 398 days (spleen group) and 1232 days (control group), 3 of 17 (17%) in the spleen group developed graft versus host disease (GVHD), whereas 1 of 23 (4.5%) in control group did (P = NS). In one patient in each group, GVHD was fatal. No patient developed posttransplant lymphoproliferative disorder (PTLD) in the spleen group, whereas 4 of 23 (17%) in the control group developed PTLD. One-year patient survival was 84% in the spleen group and 86% in the control group. Recipients of the spleen as part of a multivisceral graft had significantly lower platelet counts. Rejection-free survival may be prolonged, but the risk of GVHD may be increased.
Collapse
Affiliation(s)
- T Kato
- Divisions of Transplant, Pediatric Gastroenterology, Pediatric Critical Care Medicine, and Immunopathology, University of Miami, School of Medicine, 1801 NW 9th Avenue, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Haider H, Tzakis A, Manoharan M, Selvaggi G, Nishida S, Levi D, Ciancio G. Ureteral reconstruction and bladder augmentation using intestinal allograft in a modified multivisceral transplant patient. Am J Transplant 2006; 6:1968-71. [PMID: 16889551 DOI: 10.1111/j.1600-6143.2006.01388.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Segments of ileum are used as conduits following ureteral resection and for bladder augmentation to achieve adequate bladder capacity. We herein report the use of a segment of transplanted ileum for this purpose in a patient with Gardner's syndrome who underwent multivisceral transplantation. To our knowledge this is the first such case report.
Collapse
Affiliation(s)
- H Haider
- Department of Surgery, University of Miami, Florida, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Ueno T, Kato T, Revas K, Gaynor J, Velasco M, Selvaggi G, McLaughlin G, Hernandez E, Kramer RE, Krame R, Thompson J, Tzakis A. Growth After Intestinal Transplant in Children. Transplant Proc 2006; 38:1702-4. [PMID: 16908254 DOI: 10.1016/j.transproceed.2006.05.025] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Intestinal transplantation has been more frequent in children with intestinal failure. However, the growth after intestinal transplantation has not been well documented. The demographics, transplant information, postoperative complications, heights, and weights were obtained retrospectively from medical records on 23 children who underwent intestinal transplantation. Z-scores were calculated from the STAT Growth-BP, based on Centers for Disease Control and Prevention growth chart (2000). Transplantations were performed between 1999 and 2004. Patient median age was 1.1 years (range 0.5 to 6.9 years). Twelve were boys and 11 girls. Seventeen children received multivisceral transplantations, one modified multivisceral transplantation, and five isolated intestinal transplantations. Baseline immunosuppression consisted of tacrolimus and corticosteroids. Daclizumab was used as induction agent in 18 patients; alemtuzumab, in five patients. Median pretransplant Z-scores were median -1.67 (n = 23) in weight, and median -3.36 (n = 21) in height. Pretransplant growth was significantly retarded. We analyzed significantly retarded patients with Z-score <-2.0. The change of weight Z-score from pretransplant was: 1.25 at 6 months (n = 11), 1.46 at 12 months (n = 10), and 2.21 at 24 months (n = 7). The change of height Z-score: 1.9 at 6 months (n = 16), 1.42 at 12 months (n = 13), and 1.51 at 24 months (n = 10). Z-score significantly improved (P < .002, ANOVA). Among the analyzed factors sex, age at transplant, length of stay, and rejection within 6 months, were not associated with catch-up growth. Children with retarded growth showed significant catch-up after successful intestinal transplantation.
Collapse
Affiliation(s)
- T Ueno
- Department of Surgery, University of Miami, Miami, Florida, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Selvaggi G, Kato T, Gaynor JJ, Thompson J, Nishida S, Madariaga J, Levi D, Moon J, Ruiz P, Cantwell P, Tuteja S, Tzakis A. Analysis of Rejection Episodes in Over 100 Pediatric Intestinal Transplant Recipients. Transplant Proc 2006; 38:1711-2. [PMID: 16908257 DOI: 10.1016/j.transproceed.2006.05.061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Rejection after intestinal transplant is a significant source of morbidity and mortality. We analyzed number of rejections, severity, and duration of episodes in pediatric recipients of intestinal transplants. One hundred eighteen intestinal transplants were performed: intestine (n = 27), liver-intestine (n = 27), modified multivisceral (n = 7), and multivisceral (n = 57). A total of 186 rejections were classified: mild (n = 89), moderate (n = 70), severe (n = 27). Duration of episodes doubled for each increasing step in severity. Treatment of mild rejection was with steroids, moderate rejection was treated with OKT3, severe rejection required OKT3 and organ removal. Most rejections occurred during the first month posttransplant, with the incidence of all rejections declining after 6 months posttransplant. Intestine and liver-intestine recipients had significantly higher probability of developing severe rejections, as compared to MVT. In summary, recipients of MVT seemed to be protected from rejection as compared to intestine or liver-intestine recipients.
Collapse
Affiliation(s)
- G Selvaggi
- Division of Liver and GI Transplantation, University of Miami Miller School of Medicine, 1801 NW 9th Avenue, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Selvaggi G, Sarkar S, Mittal N, Acar BC, Weppler D, Kato T, Tryphonopoulos P, Tzakis A, Ruiz P. Etiology and Management of Alimentary Tract Ulcers in Pediatric Intestinal Transplantation Patients. Transplant Proc 2006; 38:1768-9. [PMID: 16908276 DOI: 10.1016/j.transproceed.2006.05.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Patients who undergo intestinal transplantation encounter several complications in the posttransplant period, one of them being ulcer formation in the alimentary tract. During postoperative endoscopic monitoring of 112 pediatric intestinal transplantation patients at our institution, we identified chronic ulcer formation in 11 patients. There were no common or defining demographic or clinical variables that were found in the patients with ulcers. The ulcers could be located within the allograft or in native tissue. Biopsies were obtained from the ulcer edge and the intervening mucosa as well as an evaluation of possible infectious agents. The most common changes in the ulcers were compatible with Epstein-Barr virus-associated posttransplant lymphoproliferative disorder (PTLD; seven cases), acute rejection (six cases), and less commonly, infectious causes (one case). These changes could occur concomitantly and retrospective analysis after therapy showed that the ulcers could have multiple etiologies. Directed biopsies of ulcer edges often displayed morphological changes compatible with acute rejection of the graft, although some biopsies of the intervening mucosa did not show similar changes. Some patients treated based on the changes within the intervening mucosa responded well and led to resolution of the ulcers. Our findings demonstrate that PTLD and acute rejection are the most common causes of chronic ulcer formation and that biopsy samples should be collected simultaneously from both the ulcer edge and intervening mucosa since pathological changes can vary depending on the underlying cause(s). Infectious agents were rarely present but could be seen superimposed with the underlying cause.
Collapse
Affiliation(s)
- G Selvaggi
- University of Miami, Miami, FL 33136, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Ueno T, Kato T, Gaynor J, Velasco M, Selvaggi G, Zilleruelo G, McLaughlin G, Hernandez E, Thompson J, Tzakis A. Renal Function After Pediatric Intestinal Transplant. Transplant Proc 2006; 38:1759-61. [PMID: 16908273 DOI: 10.1016/j.transproceed.2006.05.026] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Data were analyzed from 44 patients who survived more than 2 years after intestinal transplantation performed between 1994 and 2002. Median age was 1.7 years. Tacrolimus level was defined as average tacrolimus level over 6 months. Kidney function was evaluated using a 6-month average serum creatinine. Glomerular filtration rate (GFR) was calculated with the Schwartz formula. The procedures were: isolated intestinal transplantation (n = 11), liver and intestinal transplantation (n = 9), multivisceral transplantation (n = 22), and modified multivisceral transplantation (n = 2). Forty-four patients were followed for a mean of 3.6 years on tacrolimus. Tacrolimus levels ranged between 3.5 and 19.9 ng/mL (median 14.6 ng/mL) at 0 to 6 months and 6.0 to 18.9 ng/mL (median 13.2 ng/mL) at 0 to 12 months. Pretransplant kidney function as mean GFR was 138 +/- 42 mL/min/1.73 m(2) (n = 44), posttransplant kidney function at 18 to 24 month as mean GFR was 102+/-35 mL/min/1.73 m(2) (n = 44), a value that was 81% of the pretransplant GFR (P < .0001). In an analysis of tacrolimus level versus renal function, a value greater than 13.5 ng/mL during the first 12 months was a significant predictor for impaired renal function at 2 years after transplantation (defined as average GFR less than 90 mL/min/1.73 m(2) at 18 to 24 months; P = .001). Only age among age, sex, diagnosis, transplant type, and rejection episodes showed a correlation with renal function. Renal function dropped significantly at 2 years after pediatric intestinal transplantation to 81% of the pretransplantation value. Tacrolimus level for the first 12 months seemed to predict subsequent development of renal impairment at 2 years.
Collapse
Affiliation(s)
- T Ueno
- Department of Surgery, University of Miami/Jackson Memorial Medical Center, 1801 NW 9th Avenue, Miami, FL 33136, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
UNLABELLED Our previous investigations on neurodevelopmental outcomes for intestinal transplanted infants revealed that while some children were able to achieve a normal developmental outcomes, most children suffered from significant motor delays and several experienced severe cognitive delays. In our current investigation, we were especially interested in children who are transplanted before the age of 3 years because the impact of the chronic illness and nutrition impairment on the infant's developing brain may be more severe than those children who receive a liver transplant. METHODS We evaluated 34 infants using the Bayley Scales of Infant Development. Twenty-seven children received a liver/intestine or multivisceral transplant and seven received a liver transplant. RESULTS Comparison of the two groups revealed that children receiving an intestine/multivisceral transplant have much poorer outcomes. Seventy-four percent of these children were significantly delayed mentally compared to only 57.14% of the liver transplant infants. Furthermore, 42.86% of the liver-transplanted infants were actually functioning in the normal range posttransplant. The intestinal/multivisceral transplant infants' motor development shows the most striking difference, with 96.3% being severely delayed as compared to liver transplant infants in whom only 71% experienced serious delays. The neurodevelopmental impact of organ failure and transplant before the age of 3 years may depending on the type of organ transplant. Our study found that it may be more likely to expect a good outcome for liver transplant patients than for intestinal and multivisceral transplanted infants. This difference maybe due to the overall severity of the disease and the possible impact of nutritional deficits early in infancy.
Collapse
Affiliation(s)
- D M Thevenin
- Department of Pediatrics, UMMG Physician-Patient Advocacy Program, University of Miami/Miller School of Medicine, Miami, FL 33101, USA.
| | | | | | | | | | | |
Collapse
|
41
|
Thevenin DM, Baker A, Kato T, Tzakis A, Fernandez M, Dowling M. Neurodevelopmental Outcomes of Infant Multivisceral Transplant Recipients: A Longitudinal Study. Transplant Proc 2006; 38:1694-5. [PMID: 16908251 DOI: 10.1016/j.transproceed.2006.05.036] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
UNLABELLED This longitudinal investigation compares cognitive and physical capabilities of transplant recipients, both before and after receiving an intestinal transplant. METHODS Using the Bayley Scales of Infant Development, we conducted pretransplant and posttransplant assessments on nine children (4 males, 5 females) who received either an isolated intestine, combined intestine and liver, or multivisceral transplants, with a mean age at transplant of 18 months (range 8-29) and a mean time posttransplant of 2 months (range 1-4 months). RESULTS Scores on the Mental Developmental Index reflected that a majority (55.6%) of patients who scored in the significantly delayed range prior to transplant remained in the significantly delayed classification after receiving a transplant. In addition, 33.3% showed a decrease in their mental classification; either from "mildly delayed" to "significantly delayed" or from "within normal limits" to "mildly delayed". Results on the Motor Developmental Index demonstrated that 78% of recipients had significant delays both before and after receiving a transplant, while 11.1% fell one standard deviation after transplantation. We found that the majority of children who experience developmental delays prior to transplant are still experiencing delays when they are discharged from inpatient care. In addition, those children receiving multivisceral transplantations, as opposed to an isolated bowel, may be at a much greater risk of developing and retaining both cognitive and physical delays. Early neurodevelopmental evaluations of these patients is essential for early parental education and compliance with early intervention services to maximize potential recovery and ability to obtain normal development.
Collapse
Affiliation(s)
- D M Thevenin
- Department of Pediatrics, UMMG Physician-Patient Advocacy Program, University of Miami/Miller School of Medicine, Miami, FL 33101, USA.
| | | | | | | | | | | |
Collapse
|
42
|
Ueno T, Kato T, Gaynor J, Velasco M, Selvaggi G, Nishida S, Moon J, Levi D, Madariaga J, Tzakis A. Renal Dysfunction Following Adult Intestinal Transplant Under Tacrolimus-Based Immunosuppression. Transplant Proc 2006; 38:1762-4. [PMID: 16908274 DOI: 10.1016/j.transproceed.2006.05.066] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We analyzed data from the records of 24 adult patients who survived more than 2 years after intestinal transplantation performed between 1995 and 2002 under tacrolimus-based immunosuppression. Ages ranged from 19.3 to 59.2 years old (median 32.1 years). Tacrolimus cumulative level was defined as a sum of weekly average tacrolimus level over time. Kidney function was evaluated by the 6-month average serum creatinine level. Estimated creatinine clearance was calculated with the Cockcroft-Gault formula. Student's t test was used for analysis. Primary diseases were mesenteric thrombosis (n = 7), trauma (n = 4), Crohn's (n = 3), Gardner's (n = 5), and others (n = 7). Procedures were isolated intestinal transplant (n = 10), liver and intestine (n = 1), multivisceral transplant (n = 9), or modified multivisceral transplant (n = 4). Cumulative tacrolimus levels ranged between 1161 and 8623 ng*day/mL (median 4132 ng*day/mL) at 0 to 12 months. Pretransplant kidney function as mean creatinine clearance was 114 mL/min per 1.73 m(2) (n = 24). Creatinine clearance decreased to a mean of 49.6 mL/min per 1.73 m(2) (43.5% of pretransplant) at 2 years (P < .0001). The average creatinine clearance at 18 to 24 months in each patient with a cumulative tacrolimus level <4500 ng*day/mL was 63% +/- 25% of preoperative creatinine clearance. In patients with a cumulative tacrolimus level >4500 ng*day/mL, it was 34% +/- 17%. Cumulative tacrolimus level >4500 ng ng*day/mL was significantly associated with a decreased creatinine clearance at 2 years (P = .006). Renal function decreased significantly after intestinal transplantation in adults. Cumulative tacrolimus level in the first year affected renal function at 2 years.
Collapse
Affiliation(s)
- T Ueno
- Department of Surgery, University of Miami/Jackson Memorial Medical Center, 1801 NW 9th Avenue, Miami, FL 33136, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Tryphonopoulos P, Weppler D, Nishida S, Kato T, Levi D, Selvaggi G, Moon J, Madariaga JR, Delagarza J, Tzakis A, Ruiz P. Mucosal fibrosis in intestinal transplant biopsies correlates positively with the development of chronic rejection. Transplant Proc 2006; 38:1685-6. [PMID: 16908247 DOI: 10.1016/j.transproceed.2006.05.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Endoscopic biopsies of intestinal allografts are limited to the superficial layers of the bowel. We investigated whether the presence of mucosal fibrosis in graft biopsies was indicative of chronic allograft rejection. We examined graft biopsies of 182 intestinal transplant recipients for the presence of mucosal fibrosis. Kaplan-Meier analysis showed that within 5 years posttransplantation 33% of intestinal transplant patients had graft biopsies positive for mucosal fibrosis. Although the presence of mucosal fibrosis did not affect patient or graft survival, patients with this lesion were at higher risk of developing chronic allograft enteropathy.
Collapse
Affiliation(s)
- P Tryphonopoulos
- Department of Surgery and Pathology, University of Miami, 1611 NW 12th Avenue, JMH Holtz Center #2101, Miami, FL 33136, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A. Analysis of Risk Factors for the Development of Posttransplant Lymphoprolipherative Disorder Among 119 Children Who Received Primary Intestinal Transplants at a Single Center. Transplant Proc 2006; 38:1755-8. [PMID: 16908272 DOI: 10.1016/j.transproceed.2006.05.039] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
UNLABELLED Posttransplant lymphoproliferative disorder (PTLD) is a well-known complication after pediatric transplantation. We analyzed all potential risk factors to assess patient and graft outcomes of 119 children who received intestinal transplantations. MATERIALS AND METHODS Between August 1994 and March 2005, 119 patients underwent cadaveric intestinal transplantation. Their median age at transplant was 1.4 years (range: 0.6-17), median weight was 9.5 kg (range: 4.7-67), and 57% were boys. The median follow-up among 49 ongoing survivors was 41 months (range: 4-121). All PTLD cases were biopsy proven. In the past 5 years, treatment included antiviral therapy, immunosuppression withdrawal, and use of rituximab. RESULTS The incidence of PTLD was 11.8% (14/119). No patient experienced graft failure secondary to PTLD, while two patients died from PTLD (14.2%). The PTLD group was divided into an early onset group (<4 months, 6 of 14; 42.8%) and a late onset group (>2 years, 8 of 14; 57.2%). No patient experienced PTLD between 4 months and 2 years after transplantation. The use of OKT3 was the only significant risk factor for the development of PTLD. No factor was specifically associated with the early versus late development of PTLD. CONCLUSIONS The only factor associated with a significantly higher risk of PTLD was the use of OKT3 to treat a rejection episode. Finally, since the the introduction of anti-CD20 antibodies as part of the treatment protocol for PTLD, the risk of death due to PTLD appears to have become manageably low.
Collapse
Affiliation(s)
- C Quintini
- Pediatric Liver GI Transplant Program, University of Miami/Jackson Memorial Medical Center, Highland Professional Building, 1801 NW 9th Avenue, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Kato T, Mizutani K, Terasaki P, Quintini C, Selvaggi G, Thompson J, Ruiz P, Tzakis A. Association of Emergence of HLA Antibody and Acute Rejection in Intestinal Transplant Recipients: A Possible Evidence of Acute Humoral Sensitization. Transplant Proc 2006; 38:1735-7. [PMID: 16908266 DOI: 10.1016/j.transproceed.2006.05.058] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Development of HLA antibody has been associated with chronic allograft failure in kidney recipients. We tested HLA antibody in posttransplant sera of intestinal recipients: 126 sera from 28 pediatric recipients were tested for HLA antibody by flow PRA (f-PRA). Median age was 1.1 years (0.44-17). Graft types included isolated intestine (n = 6), liver and intestine (n = 3), modified multivisceral (n = 3), and multivisceral grafts (n = 16). Greater than 10% of either class I (CI) or class II (CII) f-PRA was considered positive, and >30% strongly positive. Five of 28 patients had positive f-PRA in multiple samples; the remaining 23 had either no positive or only one positive sample. Three patients had strongly positive f-PRA. Patients with multiple positive samples were recipients of two modified multivisceral and three multivisceral grafts. Only one of these patients had a positive PRA pretransplant. Cytotoxic cross-match at transplant was negative for all. The three with strongly positive f-PRA showed significant episodes of rejection around the time of positive samples. One of them who persistently had f-PRA value >80% (from day 13-113) died of refractory rejection. The other two had f-PRA of 76% and 53% during the early postoperative course with associated episodes of rejection. F-PRA value decreased with rejection therapy. Only one of the 23 patients (4%) with negative f-PRA had an episode of rejection around the time of sample collection. Development of HLA antibody after intestinal transplantation seems to have significant association with acute rejection episodes.
Collapse
Affiliation(s)
- T Kato
- Divisions of Transplant, Pediatric Gastroenterology and Immunopathology, University of Miami School of Medicine, 1801 W. 9th Avenue, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Ruiz P, Weppler D, Tryphonopoulos P, Nishida S, Moon J, Kato T, Selvaggi G, Levi D, Madariaga J, DelaGarza J, Tuteja S, Garcia M, Tzakis A. CD55 and CD59 Deficiency in Transplant Patient Populations: Possible Association With Paroxysmal Nocturnal Hemoglobinuria–Like Symptoms in Campath-Treated Patients. Transplant Proc 2006; 38:1750-2. [PMID: 16908271 DOI: 10.1016/j.transproceed.2006.05.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Campath-1H therapy is directed to CD52, a small mw protein that has a glycosylphosphatidylinositol (GPI) anchor, which has a conventional structure similar to other GPI anchors such as CD55 and CD59. Paroxysmal nocturnal hemoglobinuria (PNH) results when cells have a somatic defect in the synthesis of GPI anchors and lack CD55 and CD59, as well as CD52. Several patients treated with Campath developed PNH-like symptoms with hemolysis and thrombosis. These patients were followed after therapy by measurement of peripheral CD55 and CD59 levels and showed an increased number of cells deficient in the expression of these molecules. Thereafter we instituted a screening program for the presence of CD55/59 levels in all pretransplant patients. Our results show that 17.3% of all pretransplant samples contained abnormal (9.7% of samples) or slightly abnormal (7.6% of samples) levels of granulocytes deficient in CD55 or CD59. This high prevalence of CD55/59 deficiency in Campath-treated patients with PNH-like symptoms suggests that a lack of these molecules (including CD52) could predispose to a complication of this immunosuppressive therapy.
Collapse
Affiliation(s)
- P Ruiz
- Department of Pathology, University of Miami School of Medicine, 1611 NW 12th Avenue, JMH Holtz Center #2101, Miami, FL 33136, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Loinaz C, Kato T, Nishida S, Weppler D, Levi D, Dowdy L, Nery JR, Mittal N, Vianna R, Fortún J, De la Cruz J, Madariaga J, Tzakis A. Bacterial infections after intestine and multivisceral transplantation. The experience of the University of Miami (1994-2001). Hepatogastroenterology 2006; 53:234-42. [PMID: 16608031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
BACKGROUND/AIMS Bacterial infections (BI) are frequent after intestinal transplantation (ITx). Bacteremia, intraabdominal and respiratory infections are the leading forms. The objective of this study is to analyze the occurrence, determinants and outcome of BI. METHODOLOGY One hundred and twenty-four patients with ITx (39 isolated, 33 liver-intestine, 63 multivisceral). Only major BI were considered, including bacteremia, pneumonia, intraabdominal infections, severe wound infections. RESULTS BI occurred in 92.7% of patients during follow-up, with an average of 2.9 episodes per patient. Bacteremia was the commonest picture (1.7 per patient). More than 80% of patients had a BI before the end of the second month. Multivariate analysis showed that the presence of BI was higher during the first 2 months after Itx in patients hospitalized before Tx [p=0.029, odds ratio (OR) 5.4] and during months 3 to 6 in those treated with Zenapax (p=0.003, OR 6.2). Occurrence of BI was increased with mycophenolate mofetil treatment (p=0.045 OR 4.2). Intraabdominal infection was more frequent when reTx was needed (p=0.0178 OR 15.2), admission before Tx (p=0.034 OR 2.7), IS with MMF (p=0.004 OR 6.2) and Zenapax (p=0.026 OR 3.6). BI was the direct cause of death in 17.8% of patients, and it was present in 76.2% of patients that died. An infectious episode during the first month, a clinically manifested abdominal infection and a positive intraabdominal culture were determinants of shorter patient survival. CONCLUSIONS BI continue to be a frequent and dreadful complication after ITx. Pretransplant patient condition, IS used and postoperative complications are crucial on BI onset and outcome.
Collapse
Affiliation(s)
- C Loinaz
- Division of Transplantation, University of Miami School of Medicine, Miami, Florida, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, Madariaga J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005; 37:1217-9. [PMID: 15848674 DOI: 10.1016/j.transproceed.2004.12.042] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Recurrence of hepatitis C (HepC) has been a most difficult dilemma in liver transplantation (OLT) because the effects of immunosuppression with steroid, mycophenolate mofetil (MMF) calcineurin antagonists, and anti-interleukin-2 antibody as well as the role of preemptive antiviral therapy are uncertain. In this study, we randomized OLT recipients with HepC into two treatment arms: tacrolimus+daclizumab+MMF (study arm) versus tacrolimus+steroids+MMF (control arm). The study arm only received steroids for the treatment of biopsy-proven rejection episodes. Both arms received preemptive anti-viral therapy with Pegasys and ribavirin. The 39 enrolled patients (among 50 to be enrolled) have median follow-up of 458 days with 23 patients (8 in study arm, 15 in control arm) having reached 1 year. The incidences of rejection episodes within 0 to 3 months, 3 to 6 months, and 6 to 12 months were (study vs control): 0% vs 28%; 0% vs 6%; and 13% vs 20%; respectively (P = NS). The 1-year protocol biopsies showed advanced fibrosis (stage 3 or greater) in 20% (3 of 15) of the control arm, but none (0 of 7) of the study arm (P = NS). We compared anticipated side effects of steroids in the first 3 months (study vs control): hypertension (36% vs 58%, P = NS), PTDM (7% vs 43%, P = .02), and wound infections (14% vs 37%, P = NS). In conclusion, liver transplant recipients with HepC tolerate a steroid-free protocol. There was a trend toward reduced steroid side effects and a lower incidence of advanced fibrosis in 1-year biopsy samples among patients receiving the steroid-free protocol.
Collapse
Affiliation(s)
- T Kato
- Division of Transplant, University of Miami, Miami, Florida 33136, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Gandia C, Yu H, Santiago S, Coats E, Defaria W, Ruiz P, Tzakis A, Kleiner G. Bone marrow-derived mesenchymal stem cells augment tissue engineered enterocytes. Biol Blood Marrow Transplant 2005. [DOI: 10.1016/j.bbmt.2004.12.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Ruiz P, Soares MF, Garcia M, Nicolas M, Kato T, Mittal N, Nishida S, Levi D, Selvaggi G, Madariaga J, Tzakis A. Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression. Transplant Proc 2004; 36:386-7. [PMID: 15050168 DOI: 10.1016/j.transproceed.2004.01.094] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Posttransplant lymphoproliferative disorders (PTLD) are a frequent complication in bowel transplant recipients. Histological changes in PTLD range from expansile lymphoplasmacytic (LP) hyperplasia to frank lymphoma. Small bowel allograft biopsies obtained in the first 250 days posttransplant were retrospectively graded after patients had received induction immunosuppression with either anti-CD52 (Campath) or anti-CD25 (Zenapax) monoclonal antibodies. The biopsies were analyzed with respect to the onset intensity of lymphoplasmacytic infiltrates and presence of in situ EBV hybridization (EBER) positivity. We observed that lymphoplasmacytic infiltrates were a frequent change in all bowel transplant patients over the examined period. Campath-treated patients developed earlier LP infiltrates of mild to moderate intensity between day 1 and 100 posttransplant, thereafter decreasing to mild. No EBER positivity was detected in this group. Zenapax-treated patients presented with LP infiltrates later of mild to moderate intensity through day 100 posttransplant. However, more persistent and intense LP infiltrates was observed after day 101 in this group, including a case of lymphoma and two cases of EBER positivity. We conclude that Campath immunosuppression results in an earlier appearance of LP lesions that are generally less intense than those evident with Zenapax. We attribute these findings to the more profound immunodeficiency and cell targeting following Campath treatment.
Collapse
Affiliation(s)
- P Ruiz
- Department of Pathology, University of Miami, Miami, Florida, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|